Last reviewed 2026-05-28 · How we verify

SB-AS15 adjuvant

European Organisation for Research and Treatment of Cancer - EORTC · Phase 2 active Biologic ✓ Verified May 2026

SB-AS15 adjuvant is a Biologic drug developed by European Organisation for Research and Treatment of Cancer - EORTC. It is currently in Phase 2 development.

SB-AS15 adjuvant is an experimental treatment being studied in clinical trials for melanoma (skin cancer). The exact mechanism of SB-AS15 adjuvant is unknown, but it is being used in combination with a D1/3-MAGE-3-His fusion protein in a vaccine therapy trial.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SB-AS15 adjuvant
Sponsor	European Organisation for Research and Treatment of Cancer - EORTC
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SB-AS15 adjuvant CI brief — competitive landscape report
SB-AS15 adjuvant updates RSS · CI watch RSS
European Organisation for Research and Treatment of Cancer - EORTC portfolio CI

Frequently asked questions about SB-AS15 adjuvant

What is SB-AS15 adjuvant?

SB-AS15 adjuvant is a Biologic drug developed by European Organisation for Research and Treatment of Cancer - EORTC.

Who makes SB-AS15 adjuvant?

SB-AS15 adjuvant is developed by European Organisation for Research and Treatment of Cancer - EORTC (see full European Organisation for Research and Treatment of Cancer - EORTC pipeline at /company/european-organisation-for-research-and-treatment-of-cancer-eortc).

What development phase is SB-AS15 adjuvant in?

SB-AS15 adjuvant is in Phase 2.

Manufacturer: European Organisation for Research and Treatment of Cancer - EORTC — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing